Eisai, Biogen To Co-Develop Two Drugs To Treat Alzheimer's Disease
This article was originally published in PharmAsia News
Executive Summary
Eisai and Biogen Idec have agreed to co-develop through marketing in the EU, Japan, U.S. and other major markets the Japan-based drug maker's two treatments for Alzheimer's disease.